Upcoming Annual Meeting of Serina Therapeutics Shareholders
Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a pioneering clinical-stage biotechnology company, has exciting news for its shareholders. Serina recently disclosed that it has set November 7, 2025, as the date for its annual meeting of stockholders. This essential gathering will provide shareholders with updates, insights, and a platform for engagement.
Details About the Annual Shareholders Meeting
The specifics regarding the timing and venue for the Annual Meeting will be detailed further in the definitive proxy statement that Serina plans to file with the Securities and Exchange Commission (SEC). It's crucial for stockholders to stay tuned for these updates, as they will guide them on how to participate effectively.
Important Deadlines for Stockholders
Due to the moving date of the Annual Meeting, which exceeds a 30-day change from the previous year's meeting, the deadline for submitting stockholder proposals is set for 5:00 p.m. (Central Time) on August 15, 2025. This timeline allows adequate space for the Board of Directors to prepare the necessary materials. Proposals must adhere to Rule 14a-8 of the Securities Exchange Act of 1934 to ensure they are included.
Submission Guidelines for Proposals
Those wishing to submit stockholder proposals or director nominations under Serina's Amended and Restated Bylaws must do so in writing. Submissions should reach the Corporate Secretary at Serina's principal executive office no earlier than July 10, 2025, and no later than August 9, 2025. Timeliness is critical, and compliance with the Bylaws will determine eligibility for consideration.
Overview of Serina Therapeutics
Serina Therapeutics stands at the forefront of biopharmaceutical innovation. The company is dedicated to developing a range of drug candidates aimed at treating neurological diseases and various medical conditions. At the heart of Serina’s mission is its proprietary POZ Platform, which enhances the efficacy and safety profiles of diverse treatment modalities, including small molecules, RNA-based therapies, and antibody-drug conjugates.
Headquarters and Corporate Mission
Operating from its headquarters at the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama, Serina is committed to catering to urgent health needs through its robust research pipeline. The company’s approach not only focuses on bringing potential therapies to market but also aims at improving patient outcomes.
Serina Therapeutics encourages interested parties to seek further information about its advancements and plans by visiting their official website. Staying informed will be vital as the company continues to evolve and refine its portfolio of potential therapies.
FAQs
1. When is the annual meeting scheduled for Serina Therapeutics?
The Annual Meeting is set for November 7, 2025.
2. How can stockholders submit proposals for the meeting?
Proposals must be submitted in writing and received by the Corporate Secretary between July 10 and August 9, 2025.
3. What is Serina Therapeutics known for?
Serina is recognized for its innovative approach to developing therapies for neurological diseases and its proprietary POZ Platform technology.
4. Where is Serina located?
Serina Therapeutics is headquartered in Huntsville, Alabama.
5. How can I contact Serina Therapeutics for more information?
You can reach out via email at sriley@serinatherapeutics.com or call (256) 327-9630.
